03 May 2025
Anglo‑French Drugs & Industries (AFDIL) posted a mixed performance for the quarter and year ended 31 March 2025.
Fourth‑Quarter Highlights (Q4 FY 2025)
Revenue: ₹25.1cr, up 22.2 % from ₹20.5 crore in Q4 FY 2024.
Net Result: Loss of ₹0.4cr, reversing the ₹3.10 crore profit recorded in the same quarter last year.
Full‑Year Highlights (FY 2025)
Revenue: ₹87.8cr, down 7.8 % from ₹95.2cr in FY 2024.
Net Profit:₹7.2cr, a sharp turnaround from the ₹12.3cr loss reported in the previous fiscal year.
Despite a dip in annual sales, AFDIL returned to profitability on a full‑year basis, driven by improved margins and cost controls. However, the March quarter saw a swing to a small loss, suggesting near‑term headwinds that management will need to address.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Pre Ipo
Upcoming IPO
Unicorn
Mutual Fund License No.:
IRDA Code (1):
IRDA Code (2):
Startup India Certificate No.:
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India